Logo Image
|Articles|July 30, 2007

SRA International, Inc. to Acquire Constella Group, LLC

SRA International, Inc. to Acquire Constella Group, LLC

FAIRFAX, VA, June 20, 2007-SRA International, Inc. (NYSE: SRX), a leading provider of technology and strategic consulting services and solutions to federal government organizations, today announced the signing of a definitive agreement to acquire Constella Group, LLC, a privately-held provider of global health consulting services.

Headquartered in Durham, NC, Constella employs more than 1500 professionals organized by three interrelated service offerings: domestic health sciences, international health development, and global drug development. The domestic health sciences business provides research, technology, communications, and strategy support to U.S. government agencies charged with protecting and advancing the health of their constituents. Constella’s international health development business helps emerging nations across the world create and implement health policy, primarily through contracts with the governments of the U.S. and the United Kingdom. The global drug development business provides blue-chip pharmaceutical, biotechnology, and medical device firms with the strategic insight and services needed to take a drug, biologic or device through the development process from concept to market. The company’s combination of capabilities, domain expertise, and geographic reach enable it to offer differentiated solutions to address the world’s most complex health issues. Constella acquired two companies during calendar year 2006. Excluding pre-acquisition revenue for those two companies, Constella revenue for calendar year 2006 was approximately $169 million.

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more